Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02396134 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT02396134 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 61 participants.
The verdict
NCT02396134, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well vaccine therapy works in reducing the frequency of cytomegalovirus severe infections (events) in patients with hematologic malignancies undergoing donor stem cell transplant. Vaccines made from a peptide may help the body build an effective immune response and may reduce cytomegalovirus events after donor stem cell transplant.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL CMVpp65-A*0201 peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2015-05-21 |
| Est. Completion | 2024-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02396134
The ClinicalTrials.gov registry entry for NCT02396134 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02396134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02396134 about?
NCT02396134 is a clinical study titled "Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant". This randomized phase II trial studies how well vaccine therapy works in reducing the frequency of cytomegalovirus severe infections (events) in patients with hematologic malignancies undergoing donor stem cell transplant. Vaccines made from a peptide may help the body build an effective immune resp...
What is the current status of trial NCT02396134?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2015-05-21. Estimated completion is 2024-09-19.
What interventions are being tested in trial NCT02396134?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), CMVpp65-A*0201 peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02396134?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.